Deepak Behera, MD’s Post

【NEWS UPDATE】💥💊🌟In a groundbreaking deal, global pharmaceutical giant AstraZeneca acquires Fusion Pharmaceuticals, a leading nuclear medicine company, for a staggering $2.4 billion. 🤝💰 This strategic move signifies a major milestone in AstraZeneca's quest to revolutionize cancer treatment through targeted therapies. The acquisition brings Fusion's expertise in next-generation radiopharmaceuticals, particularly its FPI-2265 targeted alpha therapy for prostate cancer, into AstraZeneca's portfolio. By leveraging Fusion's innovative Fast-Clear™ linker technology, AstraZeneca aims to transform cancer therapy by expanding the therapeutic window of radiation therapy. With this ambitious vision, AstraZeneca solidifies its position in the nuclear medicine field and strives to improve patient outcomes worldwide. 🌍🔬💪 https://lnkd.in/dPXXJ75a #AstraZeneca #FusionPharmaceuticals #NuclearMedicine #CancerTreatment #TargetedTherapies #Radiopharmaceuticals #ProstateCancer #Innovation #PatientOutcomes #OncologyCare

Nucleus RadioPharma 𝗵𝗮𝘀 𝗳𝗼𝗿𝗴𝗲𝗱 𝗶𝘁𝘀 𝗳𝗶𝗿𝘀𝘁 𝗰𝗼𝗺𝗺𝗲𝗿𝗰𝗶𝗮𝗹 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽 𝘄𝗶𝘁𝗵 𝗔𝗥𝗧𝗕𝗜𝗢, 𝗮 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹-𝘀𝘁𝗮𝗴𝗲 𝗿𝗮𝗱𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗰𝗼𝗺𝗽𝗮𝗻𝘆, 𝘁𝗼 𝗺𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗲 𝗣𝗯𝟮𝟭𝟮-𝗿𝗮𝗱𝗶𝗼𝗹𝗮𝗯𝗲𝗹𝗲𝗱 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝗳𝗼𝗿 𝗽𝗿𝗼𝘀𝘁𝗮𝘁𝗲 𝗰𝗮𝗻𝗰𝗲𝗿 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹𝘀. This collaboration underscores Nucleus' mission as the world's first integrated development, manufacturing, and supply chain organization for radiopharmaceuticals. Focusing on addressing manufacturing and supply chain challenges, Nucleus aims to streamline production timelines and alleviate constraints in the delivery of nuclear medicines. This partnership highlights the growing interest in radiopharmaceuticals and the efforts to overcome manufacturing and logistical hurdles in the field. https://lnkd.in/ekWKq66C #Radiopharmaceuticals #SupplyChain #NuclearMedicine #HealthcareInnovation #PharmaceuticalIndustry

Big pharma investing big dollars in #radiopharmaceuticals! Radiopharmaceuticals are getting a major boost with billion-dollar investments by major pharma companies, underscoring the potential for industry growth in targeted cancer therapies. The article highlights a growing resurgence of interest in radiopharmaceuticals, with investors and large pharmaceutical companies closely monitoring pipelines from various firms. While the impact of nuclear medicine and #theranostics has been widely understood within the community for years, the industry is now getting the spotlight and investment it needs to drive meaningful patient impact in areas of high unmet clinical need. #nuclearmedicine

Molecular Partners' corporate highlights and unaudited financial results for the third quarter of 2023 include an update on their Radio-DARPin Therapy (RDT) platform, as follows. The Company presented positive preclinical data from its RDT platform in September 2023 at the European Association of Nuclear Medicine (EANM) Annual Meeting, showing that DARPins can be engineered to increase tumor uptake as well as reduce accumulation in kidneys. Additional work is ongoing to demonstrate the ability of RDT to efficiently deliver high amounts of radioactivity for effective tumor eradication. Importantly, it was shown that many of the learnings for RDT are likely to be applicable across the platform, not merely to individual targets. More details on these efforts will be presented in 2024. Molecular Partners continues to progress its RDT platform and portfolio of projects, both in-house and in partnership with Novartis, to translate and apply learnings across programs and targets. As previously announced, the tumor-associated protein Delta-like ligand 3 (DLL3) has been selected as one of the first targets of Molecular Partners’ proprietary RDT program. https://lnkd.in/dHcFEARY

Latin America's Radiopharmaceutical Challenges and Opportunities Recently, companies like Novartis have boosted investment in radiopharmaceuticals, recognizing the potential of these cancer treatments that use radioactive isotopes to target tumor cells. This investment highlights the rapid evolution of healthcare in Latin America. However, the region faces unique challenges. The complex supply chain for isotopes like Lutetium-177, vital for treatments such as Novartis's Pluvicto, points to broader logistical and regulatory issues. Despite significant strides, including the establishment of GMP-compliant labs in Chile, hurdles remain that slow the adoption and distribution of these therapies. Since 2008, local pioneers in radioligand therapy (RLT) have shown robust knowledge and enthusiasm for these treatments, though most of the continent still lacks approved radiopharmaceuticals and reimbursement policies, highlighting a disconnect between capabilities and regulatory support. For large pharmaceutical firms, securing a reliable supply chain for raw materials and isotopes is essential. This includes long-term supply agreements, adequate nuclear reactor capacity, and large-scale manufacturing facilities in strategic locations to meet growing demand in Latin America. The local industry is responding. Regulatory bodies, scientific societies, and patient groups are addressing the needs for local manufacturing, approval pathways, and market readiness. Initiatives from Therakles Pharmaceuticals AG underscore the commitment to integrating advanced treatments into local healthcare systems, focusing on developing specific cancer therapies. Collaboration between local entities and global partners offers a promising path to accelerate technology adoption, facilitating knowledge transfer and building local expertise, potentially leading to locally produced radiopharmaceuticals that meet international standards. In summary, while challenges to the widespread adoption of radiopharmaceuticals in Latin America are significant, the opportunities to improve cancer care are immense. With strategic investments, collaborative efforts, and supportive policies, the region could transform its healthcare landscape and provide hope to countless patients battling cancer. #Radiopharmaceuticals #LatinAmericaHealth #ZentynelVC #ScienceAndBusiness

PanMediso Spotlight｜Full Life's New Drug ²²⁵Ac-FL-020 Approved by the FDA On May 30, 2024, Full Life Technologies, announced that its PSMA-targeted radiopharmaceutical ²²⁵Ac-FL-020 has obtained approval from the FDA on Investigational New Drug (IND) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Headquartered in the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone, PanMediso Holdings is committed to building a global integration of industry, academia, research, diagnosis & treatment for nuclear medicine and establishing world-class preparation & production centers of medical isotope to realize the GMP-grade production and global supply of new-type isotopes, particularly Ac-225 and Ge-68, thereby bringing new power to the development of human health. #225Ac #PSMA #FullLife #FDA #IND #mCRPC

PanMediso Spotlight｜Big Moves for Nuclear Drug——Novartis April 30, 2024 - Novartis expanded its cooperation with PeptiDream on peptide discovery. PeptiDream's innovative Peptide Discovery Platform System (PDPS®) can identify and optimise novel macrocyclic peptides for potential radionuclide binding and therapeutic diagnostics. PeptiDream will receive the downpayment of $180 million and is likely to receive up to $2.71 billion in in milestone payments and sales splits! May 2 2024 - Novartis announced the acquisition of Mariana Oncology, gaining access to its pipeline of nuclear medicines, including breast, prostate and lung cancers, including the investigational small-cell lung cancer candidate MC-339. Novartis will make an upfront payment of USD 1 billion and an additional payment of USD 750 million upon achievement of predetermined milestones. As a radioligand therapy (RLT) R&D company, PanMediso Holdings will continue to concentrate on the latest industry trends, strengthen the international cooperation, and establish a close global partnership to make more innovative breakthroughs in personalized treatment and targeted therapy with aim of improving the treatment effect for patients. #Novartis #PeptiDream #MarianaOncology #nuclearmedicine #macrocyclicpeptide #pharmaceuticalcooperation 

🚀 The Future of Cancer Treatment: A New Era of Precision Medicine 🚀 The pharmaceutical landscape is undergoing a monumental shift, with billions being invested in the development of drugs that promise to target cancer with unprecedented precision. Leading the charge are therapies known as antibody-drug conjugates (ADCs), which have captured the industry's attention by delivering chemotherapy directly to tumor cells. Pfizer's colossal $43 billion acquisition of Seagen Inc. last year is a testament to the burgeoning interest in this innovative approach. But there's another groundbreaking technology quietly making waves: radiopharmaceuticals. This approach, though at a more nascent stage than ADCs, marries traditional radioactive treatment with a targeted delivery mechanism, opening new frontiers in the battle against cancer. Recent months have seen a surge in deal-making in this sector, with venture capital and acquisitions by pharmaceutical giants underscoring the growing belief in its potential. Radiation therapy, a cornerstone of cancer treatment, is evolving. The development of radiopharmaceuticals aims to overcome the limitations of external radiation by delivering radioactive particles directly to tumor cells, minimizing harm to healthy tissues and expanding the treatment's applicability beyond localized cancers. This reinvigorated interest in radiotherapy as a precise cancer-fighting tool has been significantly boosted by Novartis's successful acquisition and subsequent FDA approval of Pluvicto for advanced prostate cancer, a move that not only yielded substantial sales but also paved the way for the technology's potential to achieve mainstream success. The recent strategic acquisitions by Eli Lilly and Bristol-Myers Squibb further illustrate the industry's commitment to exploring and investing in radiopharmaceuticals. The competitive bidding for RayzeBio highlights the sector's hot prospects, fueling optimism for startups like Fusion Pharmaceuticals and Perspective Therapeutics, whose stock prices have surged in response to these developments. As we stand on the cusp of a new decade, it's clear that the future of cancer treatment lies in precision medicine. The advancements in ADCs and radiopharmaceuticals are not just scientific breakthroughs; they represent a beacon of hope for millions affected by cancer, promising treatments that are both more effective and less invasive. The journey ahead is full of promise, and as industry leaders, innovators, and healthcare professionals, we are witnessing the dawn of a new era in oncology. Let's continue to support and invest in these transformative technologies, for they hold the key to changing the face of cancer treatment forever. #CancerTreatment #Radiopharmaceuticals #PrecisionMedicine #PharmaceuticalInnovation #Oncology #Healthcare

Did you know that radiopharmaceuticals are all the rage in cancer treatment research right now? 📈 Pharma giant Novartis’ $1 billion acquisition of Mariana Oncology is proof of this growing fascination with this class of therapeutics. 💰 Other major buyouts include AstraZeneca’s $2 billion deal with Fusion Pharmaceuticals and Bristol Myers Squibb’ $4.1 billion RayzeBio purchase. 🛒 💸 More and more young biotechs have also nabbed funding in recent times to advance their radiopharmaceutical pipeline. Read our latest article to find out about some significant deals in the field this past year! 👇 https://lnkd.in/eTnaMS-Z #radiopharmaceuticals #cancertreatment #oncologyresearch #biotechinvestments #biotechfunding #medicalinnovation Eli Lilly and Company | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | Aktis Oncology | AstraZeneca | Nucleus RadioPharma | Ratio Therapeutics | Abdera Therapeutics | Convergent Therapeutics, Inc.

Radiopharm Theranostics Ltd (ASX:RAD) is celebrating today after findings from its F18-Pivalate brain glioma imaging study were published in a prestigious peer-reviewed journal. The #biotech stock, which is developing a suite of #diagnostic and #therapeutic #radiopharmaceutical products, had new data from its RAD 101 candidate documented in the European Journal of Nuclear Medicine and Molecular Imaging this week. Radiopharm is currently focused on filing an Investigational New Drug application for RAD 101 with the US Food and Drug Administration ( #FDA ) — a move it hopes will initiate a multi-centre trial for imaging brain metastasis in the current quarter. More at #Proactive #ProactiveInvestors #ASX #RAD http://ow.ly/bamE104PrIb